Table 5. Association of the CTI with dyslipidemia incidence across physical activity levels. Physical activity Variable Number of events, n Model 1 Model 2 Model 3 HR 95% CI p HR 95% CI p HR 95% CI p Light CTI (per 1-unit) 634 1.11 1.02-1.20 0.03 1.10 1.01-1.19 0.04 1.11 1.02-1.18 0.04 Q1 (Ref) 122 Q2 141 1.03 0.87-1.22 0.72 1.02 0.86-1.21 0.76 1.03 0.85-1.22 0.77 Q3 170 1.07 0.91-1.27 0.33 1.06 0.90-1.26 0.36 1.04 0.87-1.23 0.36 Q4 201 1.25 1.05-1.49 0.02 1.23 1.04-1.47 0.03 1.21 1.02-1.44 0.03 P for trend 0.02 0.03 0.03 Moderate CTI (per 1-unit) 982 1.12 1.03-1.21 0.01 1.11 1.02-1.20 0.02 1.11 1.02-1.17 0.02 Q1 (Ref) 163 Q2 218 1.01 0.86-1.18 0.90 1.01 0.86-1.18 0.91 1.01 0.84-1.17 0.93 Q3 290 1.09 0.93-1.27 0.25 1.08 0.92-1.26 0.28 1.06 0.92-1.24 0.31 Q4 311 1.28 1.09-1.50 0.01 1.26 1.07-1.49 0.01 1.24 1.05-1.46 0.02 P for trend 0.01 0.02 0.02 Vigorous CTI (per 1-unit) 395 1.30 1.08-1.56 0.01 1.29 1.07-1.55 0.01 1.26 1.05-1.53 0.02 Q1 (Ref) 95 Q2 89 1.18 0.84-1.65 0.33 1.16 0.83-1.62 0.35 1.14 0.81-1.62 0.34 Q3 82 1.25 0.90-1.74 0.15 1.23 0.88-1.72 0.18 1.21 0.86-1.72 0.20 Q4 129 1.49 1.11-2.01 0.01 1.47 1.09-1.98 0.02 1.44 1.07-1.94 0.02 P for trend 0.01 0.02 0.02 HR = hazard ratio; CI = confidence interval. Q1 denotes the lowest quartile, which served as the reference category. Model 1 included no covariate adjustment; Model 2 was adjusted for demographic and lifestyle characteristics (sex, age, residence, marital status, education, smoking, and alcohol consumption); and Model 3 additionally accounted for comorbid conditions such as chronic diseases, arthritis, liver disease, asthma, kidney disease, and gastrointestinal disorders, as well as the use of anti-diabetic medication, anti-hypertensive medication, and lipid-lowering medication as covariates. The p for trend was estimated by modeling the median value of each quartile as a continuous variable in the Cox regression model. Statistical significance was defined as a two-sided p < 0.05.